Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) $ in Millions			12 Months Ended
	Jul. 01, 2022	Jun. 30, 2022	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($) milestone	Dec. 31, 2021 USD ($)
Disaggregation of Revenue [Line Items]
Revenues			$ 13,117.2	$ 12,172.9	$ 16,071.7
Sanofi Collaboration Agreement, Antibody
Disaggregation of Revenue [Line Items]
Percentage of quarterly profits require to be paid for reimbursement of development costs			10.00%
Percentage of share of profits used to reimburse collaborating party for trial costs	20.00%	10.00%
Contingent reimbursement obligation			$ 2,330.0
Starting share of profits outside the United States, based on sales, for collaborating party			65.00%
Starting share of profits outside the United States, based on sales, for company			35.00%
Ending share of profits outside the United States, based on sales, for collaborating party			55.00%
Ending share of profits outside the United States, based on sales, for company			45.00%
Number of sales-based milestones | milestone				2
Sanofi Collaboration Agreement, Antibody | Second Milestone
Disaggregation of Revenue [Line Items]
Revenues					50.0
Levels of twelve month sales at which sales milestone payments would be received					$ 1,500.0
Period for achieving sales target for milestone payment, rolling basis					12 months
Sanofi Collaboration Agreement, Antibody | Third Milestone
Disaggregation of Revenue [Line Items]
Revenues				$ 50.0
Levels of twelve month sales at which sales milestone payments would be received				$ 2,000.0
Period for achieving sales target for milestone payment, rolling basis				12 months
Sanofi Collaboration Agreement, Antibody | Sales Milestone Four
Disaggregation of Revenue [Line Items]
Revenues				$ 50.0
Levels of twelve month sales at which sales milestone payments would be received				$ 2,500.0
Period for achieving sales target for milestone payment, rolling basis				12 months
Sanofi Collaboration Agreement, Antibody | Sales Milestone Five
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, variable consideration amount			$ 50.0
Levels of twelve month sales at which sales milestone payments would be received			$ 3,000.0
Period for achieving sales target for milestone payment, rolling basis			12 months
Sanofi Collaboration Agreement, Antibody | Minimum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party			80.00%
Percentage of quarterly profits require to be paid for reimbursement of development costs			30.00%
Sanofi Collaboration Agreement, Antibody | Maximum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party			100.00%
Percentage of quarterly profits require to be paid for reimbursement of development costs			50.00%